June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Intravitreal Injection of Bevacizumab for Macula Edema Secondary to Central Retinal Vein Occlusion: Efficacy at 1 Day after Injection
Author Affiliations & Notes
  • Atsushi Ishikawa
    Teikyo University, Kawasaki, Japan
  • Yutaka Imamura
    Teikyo University, Kawasaki, Japan
  • Moe Mita-Takahashi
    Teikyo University, Kawasaki, Japan
  • Rieko Higashida
    Teikyo University, Kawasaki, Japan
  • Yorihisa Tsutsumi
    Teikyo University, Kawasaki, Japan
  • Yoshikazu Ichikawa
    Teikyo University, Kawasaki, Japan
  • Masahiro Ishida
    Teikyo University, Kawasaki, Japan
  • Footnotes
    Commercial Relationships Atsushi Ishikawa, None; Yutaka Imamura, None; Moe Mita-Takahashi, None; Rieko Higashida, None; Yorihisa Tsutsumi, None; Yoshikazu Ichikawa, None; Masahiro Ishida, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 5846. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Atsushi Ishikawa, Yutaka Imamura, Moe Mita-Takahashi, Rieko Higashida, Yorihisa Tsutsumi, Yoshikazu Ichikawa, Masahiro Ishida; Intravitreal Injection of Bevacizumab for Macula Edema Secondary to Central Retinal Vein Occlusion: Efficacy at 1 Day after Injection. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5846. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the visual and anatomical outcome in eyes with macular edema secondary to central retinal vein occlusion (CRVO) at 1 day after injection of intravitreal bevacizumab.

 
Methods
 

A retrospective, consecutive case series identified 20 consecutive patients with CRVO undergoing intravitreal injection of bevacizumab. Optical coherence tomography images were taken at the day of injection and 1-day after injection. Retinal thickness at fovea, height of serous retinal detachment and visual acuity were monitored before and after injection.

 
Results
 

The mean age of patients was 67.8 years old (6 females). Retinal thickness at fovea was 726 ± 281 µm before injection and was 440 ± 264 µm at 1 day after injection. (Student t test, P=0.0020) Height of retinal detachment was 221±215 µm before injection and 139±176 µm 1-day after injection. (P=0.264) Visual acuity (logMAR) was 0.762±0.477 before injection and 0.713±0.436 at 1 day after injection. (P=0.732)

 
Conclusions
 

Rapid resolution of intraretinal fluids was observed in CRVO, however significant improvement of vision was not observed at 1 day after injection.

  
Keywords: 688 retina • 550 imaging/image analysis: clinical • 585 macula/fovea  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×